应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
DNLI Denali Therapeutics Inc.
交易中 03-26 13:50:55 EDT
20.12
-2.35
-10.46%
最高
22.58
最低
19.93
成交量
201.06万
今开
22.53
昨收
22.47
日振幅
11.79%
总市值
31.91亿
流通市值
28.97亿
总股本
1.59亿
成交额
4,203万
换手率
1.40%
流通股本
1.44亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
美国FDA批准Avlayah用于治疗亨特综合征神经系统症状
投资观察 · 03-26 00:11
美国FDA批准Avlayah用于治疗亨特综合征神经系统症状
Denali Therapeutics宣布美国FDA批准Avlayah™（Tividenofusp Alfa-Eknm）用于治疗亨特综合征（MPS II）
美股速递 · 03-25 23:51
Denali Therapeutics宣布美国FDA批准Avlayah™（Tividenofusp Alfa-Eknm）用于治疗亨特综合征（MPS II）
Denali Therapeutics Inc. 新药Avlayah获批后即将登陆美国市场，采用每周一次给药方案
美股速递 · 03-25 23:51
Denali Therapeutics Inc. 新药Avlayah获批后即将登陆美国市场，采用每周一次给药方案
Denali Therapeutics公布2025年第四季度及全年财务业绩与业务亮点
美股速递 · 02-27
Denali Therapeutics公布2025年第四季度及全年财务业绩与业务亮点
Denali Therapeutics将公布酶转运载体项目数据，聚焦亨特综合征、A型桑菲利波综合征及庞贝病治疗进展
美股速递 · 01-30
Denali Therapeutics将公布酶转运载体项目数据，聚焦亨特综合征、A型桑菲利波综合征及庞贝病治疗进展
Denali Therapeutics公布2026年关键预期里程碑与优先事项 含Hunter综合征疗法Tividenofusp Alfa的商业化上市
美股速递 · 01-06
Denali Therapeutics公布2026年关键预期里程碑与优先事项 含Hunter综合征疗法Tividenofusp Alfa的商业化上市
12月24日美股盘前要闻
钛媒体快报 · 2025-12-24
12月24日美股盘前要闻
Denali Therapeutics：拟发行并出售2亿美元普通股及部分投资者的认股权证
美股速递 · 2025-12-10
Denali Therapeutics：拟发行并出售2亿美元普通股及部分投资者的认股权证
Denali Therapeutics Inc - Royalty Pharma将从Denali获得Tividenofusp Alfa全球销售9.25%的版税
美股速递 · 2025-12-04
Denali Therapeutics Inc - Royalty Pharma将从Denali获得Tividenofusp Alfa全球销售9.25%的版税
Denali Therapeutics 第三季度运营支出为1.37434亿美元
投资观察 · 2025-11-20
Denali Therapeutics 第三季度运营支出为1.37434亿美元
Denali Therapeutics Inc.：认为修正案中提交的更新信息不会影响BLA的临床药理学或获益风险结论
美股速递 · 2025-10-14
Denali Therapeutics Inc.：认为修正案中提交的更新信息不会影响BLA的临床药理学或获益风险结论
Denali Therapeutics宣布其治疗MPS II型（亨特综合征）药物Tividenofusp Alfa的生物制品许可申请获FDA审查延期
美股速递 · 2025-10-14
Denali Therapeutics宣布其治疗MPS II型（亨特综合征）药物Tividenofusp Alfa的生物制品许可申请获FDA审查延期
Denali Therapeutics Inc.盘中异动 快速上涨5.08%
市场透视 · 2025-10-10
Denali Therapeutics Inc.盘中异动 快速上涨5.08%
B of A Securities：维持Denali Therapeutics(DNLI.US)评级，由买入调整至买入评级, 目标价由30.00美元调整至28.00美元。
金融界 · 2025-03-11
B of A Securities：维持Denali Therapeutics(DNLI.US)评级，由买入调整至买入评级, 目标价由30.00美元调整至28.00美元。
Denali Therapeutics Inc.盘中异动 早盘急速跳水5.03%
市场透视 · 2025-03-10
Denali Therapeutics Inc.盘中异动 早盘急速跳水5.03%
Denali Therapeutics Inc.2024财年实现净利润-4.23亿美元，同比减少191.72%
市场透视 · 2025-03-08
Denali Therapeutics Inc.2024财年实现净利润-4.23亿美元，同比减少191.72%
Denali Therapeutics Inc.盘中异动 早盘股价大跌5.55%报15.40美元
市场透视 · 2025-03-06
Denali Therapeutics Inc.盘中异动 早盘股价大跌5.55%报15.40美元
B. Riley Securities：重申Denali Therapeutics(DNLI.US)评级，由买入调整至买入评级, 目标价由38.00美元调整至35.00美元。
金融界 · 2025-03-06
B. Riley Securities：重申Denali Therapeutics(DNLI.US)评级，由买入调整至买入评级, 目标价由38.00美元调整至35.00美元。
奥本海默：维持Denali Therapeutics(DNLI.US)评级，由优于大市调整至优于大市评级, 目标价由50.00美元调整至42.00美元。
金融界 · 2025-03-04
奥本海默：维持Denali Therapeutics(DNLI.US)评级，由优于大市调整至优于大市评级, 目标价由50.00美元调整至42.00美元。
Denali Therapeutics Inc.盘中异动 快速下跌5.07%
市场透视 · 2025-03-04
Denali Therapeutics Inc.盘中异动 快速下跌5.07%
加载更多
公司概况
公司名称：
Denali Therapeutics Inc.
所属市场：
NASDAQ
上市日期：
--
主营业务：
Denali Therapeutics Inc.于2013年10月在特拉华州注册成立。他们的目标是发现和开发可以战胜神经退行性疾病的治疗药物。神经退化代表了他们那个时代最重要的未得到满足的医疗需求之一，比如阿尔茨海默病，帕金森病疾病，肌萎缩性侧索硬化症或ALS，以及其他神经退化性疾病。这些疾病对患者和社会的负担是巨大的。他们相信现在正是他们利用强有力和雄心勃勃的努力来打败神经退化的正确时机。他们相信，他们可以在一个很少成功的领域取得了成就，因为他们拥有丰富的成功经验、热忱的科学家和药物开发者团队，他们专注的科学战略，以及他们专有的血脑屏障（BBB）平台输送技术。他们正在开发广泛的神经退行性疾病靶向治疗候选药物组合，并且最近开始了他们的第一个临床试验。他们于2015年5月开始运营。
发行价格：
--
{"stockData":{"symbol":"DNLI","market":"US","secType":"STK","nameCN":"Denali Therapeutics Inc.","latestPrice":20.12,"timestamp":1774547454375,"preClose":22.47,"halted":0,"volume":2010598,"delay":0,"changeRate":-0.10458388963061852,"floatShares":144000000,"shares":158591491,"eps":-2.969999,"marketStatus":"交易中","change":-2.35,"latestTime":"03-26 13:50:55 EDT","open":22.53,"high":22.58,"low":19.9301,"amount":42027091.683635995,"amplitude":0.117931,"askPrice":20.12,"askSize":255,"bidPrice":20.06,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-2.969999,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1774555200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1512709200000,"exchange":"NASDAQ","adjPreClose":22.47,"preHourTrading":{"tag":"盘前","latestPrice":22.72,"preClose":22.47,"latestTime":"09:28 EDT","volume":4398,"amount":98407.11915,"timestamp":1774531716083,"change":0.25,"changeRate":0.011126,"amplitude":0.027592},"postHourTrading":{"tag":"盘后","latestPrice":22,"preClose":22.47,"latestTime":"19:23 EDT","volume":80588,"amount":1809362.1384,"timestamp":1774481000775,"change":-0.47,"changeRate":-0.020917,"amplitude":0.035603},"volumeRatio":1.07506,"impliedVol":0.7298,"impliedVolPercentile":0.4303},"requestUrl":"/m/hq/s/DNLI","defaultTab":"news","newsList":[{"id":"1141357973","title":"美国FDA批准Avlayah用于治疗亨特综合征神经系统症状","url":"https://stock-news.laohu8.com/highlight/detail?id=1141357973","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141357973?lang=zh_cn&edition=full","pubTime":"2026-03-26 00:11","pubTimestamp":1774455092,"startTime":"0","endTime":"0","summary":"3月25日——美国食品药品监督管理局（FDA）宣布：正式批准生物制药公司Denali Therapeutics Inc.研发的Avlayah药物，用于治疗亨特综合征引发的神经系统临床表现。\n该审批标志着针对这一罕见遗传病神经症状的疗法取得重要突破。亨特综合征患者因酶缺陷导致糖胺聚糖在体内积聚，常引发进行性神经系统损伤。此次获批将为患者提供新的治疗选择。\n（消息来源：路透社即时新闻 2026年3月25日15时50分28秒格林威治时间）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4548","BK4139","DNLI"],"gpt_icon":0},{"id":"1157962788","title":"Denali Therapeutics宣布美国FDA批准Avlayah™（Tividenofusp Alfa-Eknm）用于治疗亨特综合征（MPS II）","url":"https://stock-news.laohu8.com/highlight/detail?id=1157962788","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157962788?lang=zh_cn&edition=full","pubTime":"2026-03-25 23:51","pubTimestamp":1774453875,"startTime":"0","endTime":"0","summary":"Denali Therapeutics Inc. (DNLI) 宣布，其创新疗法Avlayah™（Tividenofusp Alfa-Eknm）已获得美国食品药品监督管理局（FDA）的正式批准，用于治疗亨特综合征（MPS II）。这一重要进展标志着该公司在罕见病治疗领域取得了关键突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4139","DNLI","BK4535"],"gpt_icon":0},{"id":"1152352342","title":"Denali Therapeutics Inc. 新药Avlayah获批后即将登陆美国市场，采用每周一次给药方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1152352342","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152352342?lang=zh_cn&edition=full","pubTime":"2026-03-25 23:51","pubTimestamp":1774453871,"startTime":"0","endTime":"0","summary":"Denali Therapeutics Inc. 宣布，其研发的新药Avlayah在获得监管批准后，将很快在美国市场供应。该药物的一大亮点是其给药频率为每周一次，有望为患者提供更便捷的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4548","DNLI","BK4139"],"gpt_icon":0},{"id":"1172288563","title":"Denali Therapeutics公布2025年第四季度及全年财务业绩与业务亮点","url":"https://stock-news.laohu8.com/highlight/detail?id=1172288563","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172288563?lang=zh_cn&edition=full","pubTime":"2026-02-27 05:02","pubTimestamp":1772139771,"startTime":"0","endTime":"0","summary":"Denali Therapeutics Inc. (DNLI) 近日披露了其2025年第四季度及全年的财务报告，并同步分享了公司在此期间取得的重要业务进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4548","BK4139","DNLI"],"gpt_icon":0},{"id":"1130865050","title":"Denali Therapeutics将公布酶转运载体项目数据，聚焦亨特综合征、A型桑菲利波综合征及庞贝病治疗进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1130865050","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130865050?lang=zh_cn&edition=full","pubTime":"2026-01-30 05:00","pubTimestamp":1769720422,"startTime":"0","endTime":"0","summary":"Denali Therapeutics Inc.近日宣布，将在2026年世界研讨会上展示其酶转运载体技术平台在亨特综合征、A型桑菲利波综合征以及庞贝病治疗领域的多项研究数据。此次公布的数据将涵盖临床前及早期临床研究结果，重点展示酶转运载体技术在突破血脑屏障、提升治疗效率方面的潜力。公司表示，这些数据的发布将为进一步推进罕见病治疗方案的临床开发提供重要科学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","DNLI","BK4535","BK4139"],"gpt_icon":0},{"id":"1153996693","title":"Denali Therapeutics公布2026年关键预期里程碑与优先事项 含Hunter综合征疗法Tividenofusp Alfa的商业化上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1153996693","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153996693?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:12","pubTimestamp":1767705146,"startTime":"0","endTime":"0","summary":"Denali Therapeutics Inc. (DNLI) 近日披露了公司2026年的战略路线图，其中最具里程碑意义的规划涉及治疗亨特综合征（Hunter Syndrome）的创新疗法Tividenofusp Alfa的正式商业化推进。该生物制药企业明确将此项产品的市场投放列为明年核心优先任务之一，标志着其在罕见病治疗领域的重要布局即将进入收获阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4548","BK4139","DNLI"],"gpt_icon":0},{"id":"2593477294","title":"12月24日美股盘前要闻","url":"https://stock-news.laohu8.com/highlight/detail?id=2593477294","media":"钛媒体快报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593477294?lang=zh_cn&edition=full","pubTime":"2025-12-24 21:43","pubTimestamp":1766583786,"startTime":"0","endTime":"0","summary":"钛媒体App 12月24日消息，美股盘前要闻：1. 美国股指期货小幅波动，截至目前，道琼斯指数期货跌0.10%，标普500指数期货跌0.04%，纳斯达克100指数期货跌0.05%。美光此前透露，2026年全年HBM已全部售罄。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224215236a6caa8d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224215236a6caa8d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1868836591.USD","LU2746668974.SGD","LU2065171311.SGD","LU2087621335.USD","LU0011850046.USD","GB00BDT5M118.USD","LU0127658192.USD","IE0004445015.USD","BK4554","LU2023250504.SGD","LU2083900584.USD","LU2746668461.USD","LU1791710582.SGD","SGXZ31699556.SGD","IE00BJLML261.HKD","LU0912757837.SGD","LU0265550946.USD","LU1506573853.SGD","LU0708995401.HKD","BK4550","LU1720051017.SGD","LU0256863902.USD","LU0109392836.USD","IE00B1BXHZ80.USD","LU0069063385.USD","MACW.SI","IE00BN29S564.USD","LU0942090050.USD","LU0053666078.USD","LU1699723380.USD","LU1868836757.USD","LU1989772840.SGD","SG9999015341.SGD","LU0494093205.USD","LU1582987324.SGD","IE00BJJMRY28.SGD","SG9999015358.SGD","LU2403377893.USD","LU0072462426.USD","BK4532","IE00BLSP4452.SGD","LU2237438978.USD","LU2471134879.HKD","BK4501","LU1035775433.USD","IE00BWXC8680.SGD","LU0124676726.USD","BK4515","LU0642271901.SGD","LU0949170426.SGD","BK4533","IE00B775SV38.USD","LU1206712785.SGD","HK0000306701.USD","LU0345770308.USD","LU0234572021.USD","LU1852331112.SGD","LU2023250843.SGD","LU0048584097.USD","IE000YTNTUN2.SGD","LU0170899867.USD","LU1145028129.USD","LU1732799900.SGD","LU2237443895.HKD","LU2092627202.USD","LU2896262040.SGD","LU2592432038.USD","LU2237443549.SGD","IE00B4YYXB79.USD","LU1496350171.SGD","LU2133065610.SGD","IE00B1XK9C88.USD","LU0210533765.USD","OEX","SG9999014898.SGD","IE000KEQY171.SGD","LU0354030438.USD","BK4585","LU0345768740.USD","LU0795875169.SGD","LU0957791311.USD","LU2487616109.SGD","LU0314104364.USD","LU1917777945.USD","LU0061474960.USD","LU1935043536.SGD","BK4507","LU0823434740.USD","IE000W1ABFV2.USD","IE0034235303.USD","LU1642822529.SGD","IE00BBT3K403.USD","LU0726765562.USD","LU0203201768.USD","LU0308772762.SGD","SG9999014542.SGD","LU2361045086.USD","LU2065170008.USD","LU0077335932.USD","LU0061475181.USD","LU2168564149.EUR","IE0004445239.USD","BK4512","LU0154236417.USD","LU2191332357.HKD","LU2456880835.USD","LU0889565833.HKD","LU0640476718.USD","LU1935042215.USD","LU1066051811.HKD","SG9999014575.USD","BK4566","LU2168564495.EUR","LU0079474960.USD","SG9999018857.SGD","LU0210528500.USD","MESmain","IE00BSNM7G36.USD","LU2430703251.USD","LU0820562030.AUD","LU1791710400.SGD","LU2750360641.GBP","IE0005OL40V9.USD","LU1551013342.USD","LU1301847155.USD","IE000ITXATA3.USD","IE00B4JS1V06.HKD","IE0004091025.USD","LU1003077747.HKD","LU2756315664.SGD","SG9999015978.USD","LU2237443382.USD","SG9999002232.USD","LU2023250330.USD","LU1571399168.USD","LU0784385840.USD","BK4575","SG9999000418.SGD","LU0238689110.USD","LU0545039389.USD","LU0861579265.USD","LU2505996509.AUD","LU2168564065.EUR","LU2236285917.USD","IE00BKVL7J92.USD","LU1868837136.USD","IE00B19Z8W00.USD","BK4571","IE00BN8TJ469.HKD","LU1235294995.USD","LU2087625088.SGD","IE00B7KXQ091.USD","LU0466842654.USD","SG9999015986.USD","SG9999002224.SGD","LU1674673691.USD","LU0784383803.USD","LU2242649171.HKD","LU2237443622.USD","LU0964807845.USD","LU0203202063.USD","LU0724617625.USD","LU0056508442.USD","LU2265009873.SGD","LU0251132253.USD","LU1066053197.SGD","IE00BJTD4N35.SGD","LU1548497426.USD","LU2097344357.USD","BK4598","LU1496350502.SGD","BK4574","LU0957808578.USD","LU2471134952.CNY","LU1582987597.SGD","SH","LU0661504455.SGD","LU2552382058.USD","IE00BLSP4239.USD","LU0289739343.SGD","LU1046421795.USD","LU1084165304.USD","IE00BK4W5M84.HKD","LU0157215616.USD","LU1989764748.USD","LU2250418816.HKD","LU0057025933.USD","LU2417539215.USD","LU2471134796.USD","IE00BFSS7M15.SGD","LU1989771016.USD","LU2381873111.SGD","LU0354030511.USD","LU0965508806.USD","IE00B3SWFQ91.USD","SG9999014567.USD","LU2860962120.EUR","LU2077746001.SGD","LU2108987350.USD","LU0820561818.USD","BK4170","SG9999014914.USD","BK4534","LU0080751232.USD","IE00B19Z8X17.USD","LU1582986433.USD","LU0444973449.USD","LU0256863811.USD","LU2357305700.SGD","LU0215105999.USD","LU1914381329.SGD","LU0348723411.USD","LU1823568750.SGD","LU1935042488.USD","LU0210536198.USD","LU2361044865.SGD","SG9999017495.SGD","BK4505","LU1989764664.SGD","IE00B5949003.HKD","LU1551013425.SGD","LU2168563687.JPY","LU2023251221.USD","IE00B3S45H60.SGD","ESmain","LU2430703178.SGD","LU2065169927.USD","LU1366333091.USD","IE00BK4W5L77.USD","SG9999018865.SGD","BK4576","LU2247934214.USD","LU1732800096.USD","LU1037948541.HKD","LU0289961442.SGD","PATH","LU2347655073.USD","LU0965509010.AUD","LU1629891620.HKD","LU1261432733.SGD","SG9999015945.SGD","LU1839511570.USD","IE00BJTD4V19.USD","LU0689472784.USD","SG9999014880.SGD","LU0823421416.USD","LU0683600562.USD","LU2452424414.USD","LU2552382215.SGD","BK4579","LU0528227936.USD","HK0000306685.HKD","LU0198837287.USD","LU1366192091.USD","LU0788109477.HKD","LU1280957306.USD","LU2471134523.USD","LU0787776722.HKD","LU1778281490.HKD","LU0097036916.USD","SG9999014906.USD","LU2271345857.HKD","LU1116320737.USD","LU0265550359.USD","IE00BJJMRX11.SGD","LU1066051498.USD","LU1674673428.USD","LU0096362180.USD","LU1127390331.HKD","LU0476273544.USD",".SPX","DNLI","LU1119994496.HKD","LU0345768153.USD","LU1244550577.SGD","LU0943347566.SGD","LU2089283258.USD","LU2602419157.SGD","LU0267386448.USD","BK4553","LU2462157665.USD","LU0323591593.USD","IE00B775H168.HKD","IE0004086264.USD","LU0096364046.USD","LU1291159041.SGD","SDS","BK4504","LU2054465674.USD","LU2092937148.SGD","IE00BFSS8Q28.SGD","LU1989772923.USD","LU2361044949.HKD","LU0868494708.USD","LU1244550221.USD","LU0109391861.USD","LU2461242641.AUD","SSO","LU0868494617.USD","BK4588","BK4592","LU0820561909.HKD","HK0000320264.USD","LU1242518857.USD","IVV","LU0472753341.HKD","LU2213496289.HKD","LU2286300806.USD","SG9999001424.SGD","HK0000320223.HKD","LU0345769128.USD","LU0345769631.USD","LU2125154935.USD","LU2756315318.SGD","LU2360106780.USD","LU1815333072.USD","LU0672654240.SGD","LU1206713676.USD","LU0949170772.SGD","LU1720051108.HKD","BK4559","LU0320765059.SGD","LU1934455863.HKD","SPXU","LU2543165471.USD","LU1316542783.SGD","SG9999015952.SGD","IE0001KFT4U8.USD","LU0234570918.USD","LU0795875086.SGD","LU2505996681.GBP","LU1935043023.USD","LU0719512351.SGD","LU0553294199.USD","SNY","LU1815336760.USD","LU0689626769.HKD","LU2089284900.SGD","UPRO","LU2125154778.USD","LU0070217475.USD","LU1069344957.HKD","LU0511384066.AUD","LU0353189680.USD","LU0965509283.SGD","LU2360032135.SGD","LU1935042991.SGD","LU2111349929.HKD","LU0784385170.HKD","LU2097344431.USD","LU1934455277.USD","LU2065171402.SGD","LU0823421333.USD","LU1116320901.HKD","LU2168564222.USD","LU0979878070.USD","LU0417517546.SGD","LU1868837300.USD","LU2242650005.HKD","LU0314106906.USD","LU0345770993.USD","LU2430703095.HKD","LU0082616367.USD","LU0882574139.USD","LU1803068979.SGD","LU1974910355.USD","SPY","LU0823434583.USD","IE0009G5SDU7.USD","LU2106854487.HKD","LU0158827948.USD","LU2028103732.USD","LU1814569148.SGD","BK4573","LU1066051225.USD","LU1242518931.SGD","LU1244550494.USD","IE00BKDWB100.SGD","BK4527","LU2237443978.SGD","LU1037948897.HKD","LU1582986359.USD","LU1804176565.USD","LU0158827781.USD","OEF","SG9999014559.SGD","LU2420271590.USD","LU0353189763.USD","LU2237443465.HKD","LU0965509101.SGD","LU1868836914.USD","LU0784384876.USD","LU1232071149.USD","LU0444971666.USD","BK4581","LU0786609619.USD","LU2458330169.SGD","LU2458330243.SGD","LU0738911758.USD","IE00BZ1G4Q59.USD","LU2347655156.SGD","LU2552382132.HKD","LU1267930730.SGD","LU1934455194.USD","LU0456855351.SGD","LU0316494557.USD","LU2063271972.USD","LU1718418525.SGD","LU2750360997.AUD","IE00B19Z9505.USD","IE0003U64NQ7.SGD","LU0149725797.USD","LU0985320562.USD","IE0009356076.USD"],"gpt_icon":1},{"id":"1115187360","title":"Denali Therapeutics：拟发行并出售2亿美元普通股及部分投资者的认股权证","url":"https://stock-news.laohu8.com/highlight/detail?id=1115187360","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115187360?lang=zh_cn&edition=full","pubTime":"2025-12-10 05:16","pubTimestamp":1765314998,"startTime":"0","endTime":"0","summary":"Denali Therapeutics：拟发行并出售2亿美元普通股及部分投资者的认股权证","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4139","DNLI","BK4535"],"gpt_icon":0},{"id":"1196397467","title":"Denali Therapeutics Inc - Royalty Pharma将从Denali获得Tividenofusp Alfa全球销售9.25%的版税","url":"https://stock-news.laohu8.com/highlight/detail?id=1196397467","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196397467?lang=zh_cn&edition=full","pubTime":"2025-12-04 20:03","pubTimestamp":1764849784,"startTime":"0","endTime":"0","summary":"Denali Therapeutics Inc - Royalty Pharma将从Denali获得Tividenofusp Alfa全球销售9.25%的版税","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4548","RPRX","BK4535","DNLI","BK4007"],"gpt_icon":0},{"id":"1153151230","title":"Denali Therapeutics 第三季度运营支出为1.37434亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153151230","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153151230?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:02","pubTimestamp":1763571770,"startTime":"0","endTime":"0","summary":"11月6日 - Denali Therapeutics 第三季度运营收入为 -1.37434亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4548","BK4139","DNLI"],"gpt_icon":0},{"id":"1107604061","title":"Denali Therapeutics Inc.：认为修正案中提交的更新信息不会影响BLA的临床药理学或获益风险结论","url":"https://stock-news.laohu8.com/highlight/detail?id=1107604061","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107604061?lang=zh_cn&edition=full","pubTime":"2025-10-14 04:02","pubTimestamp":1760385744,"startTime":"0","endTime":"0","summary":"Denali Therapeutics Inc.：认为修正案中提交的更新信息不会影响BLA的临床药理学或获益风险结论","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","DNLI","BK4139","BK4535"],"gpt_icon":0},{"id":"1180876487","title":"Denali Therapeutics宣布其治疗MPS II型（亨特综合征）药物Tividenofusp Alfa的生物制品许可申请获FDA审查延期","url":"https://stock-news.laohu8.com/highlight/detail?id=1180876487","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180876487?lang=zh_cn&edition=full","pubTime":"2025-10-14 04:02","pubTimestamp":1760385742,"startTime":"0","endTime":"0","summary":"Denali Therapeutics宣布其治疗MPS II型（亨特综合征）药物Tividenofusp Alfa的生物制品许可申请获FDA审查延期","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4548","BK4139","DNLI"],"gpt_icon":0},{"id":"2574961441","title":"Denali Therapeutics Inc.盘中异动 快速上涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574961441","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574961441?lang=zh_cn&edition=full","pubTime":"2025-10-10 01:47","pubTimestamp":1760032034,"startTime":"0","endTime":"0","summary":"北京时间2025年10月10日01时47分，Denali Therapeutics Inc.股票出现异动，股价急速上涨5.08%。Denali Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.16%。其相关个股中，Turn Therapeutics Inc.、Biodexa Pharmaceuticals Plc、Galecto, Inc.涨幅较大，Cdt Equity Inc.、Alaunos Therapeutics, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为1774.80%、1061.38%、960.23%，振幅较大的相关个股有Turn Therapeutics Inc.、Galecto, Inc.、Briacell Therapeutics Corp C/Wts 26/02/2026，振幅分别为218.60%、47.42%、42.25%。Denali Therapeutics Inc.公司简介：Denali Therapeutics Inc是一家生物技术公司，致力于开发和探索战胜神经变性疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010014714a4588c50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010014714a4588c50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","LENZ","DNLI","BK4539","BK4007","BK4535","BK4139"],"gpt_icon":0},{"id":"2518082312","title":"B of A Securities：维持Denali Therapeutics(DNLI.US)评级，由买入调整至买入评级, 目标价由30.00美元调整至28.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518082312","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518082312?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:02","pubTimestamp":1741626170,"startTime":"0","endTime":"0","summary":"B of A Securities：维持Denali Therapeutics(DNLI.US)评级，由买入调整至买入评级, 目标价由30.00美元调整至28.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11010248641320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["DNLI","LENZ"],"gpt_icon":0},{"id":"2518385208","title":"Denali Therapeutics Inc.盘中异动 早盘急速跳水5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518385208","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518385208?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:47","pubTimestamp":1741614463,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时47分，Denali Therapeutics Inc.股票出现波动，股价快速下跌5.03%。Denali Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.30%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2636.55%、601.31%、91.59%，振幅较大的相关个股有Scisparc Ltd.、Impact Biomedical, Inc.、Trevi Therapeutics, Inc.，振幅分别为40.24%、28.59%、25.35%。Denali Therapeutics Inc.公司简介：Denali Therapeutics Inc是一家生物技术公司，致力于开发和探索战胜神经变性疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214743abf30282&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214743abf30282&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DNLI","BK4548","LENZ","BK4535","BK4139"],"gpt_icon":0},{"id":"2517453968","title":"Denali Therapeutics Inc.2024财年实现净利润-4.23亿美元，同比减少191.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517453968","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517453968?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363252,"startTime":"0","endTime":"0","summary":"3月8日，Denali Therapeutics Inc.公布财报，公告显示公司2024财年净利润为-4.23亿美元，同比减少191.72%；其中营业收入为0.00美元，每股基本收益为-2.57美元。机构评级：截至2025年3月8日，当前有16家机构对Denali Therapeutics Inc.目标价做出预测，其中目标均价为36.94美元，其中最低目标价为24.00美元，最高目标价为80.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000228abed66a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000228abed66a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DNLI","LENZ"],"gpt_icon":0},{"id":"2517162354","title":"Denali Therapeutics Inc.盘中异动 早盘股价大跌5.55%报15.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517162354","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517162354?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:33","pubTimestamp":1741271613,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时33分，Denali Therapeutics Inc.股票出现波动，股价急速跳水5.55%。截至发稿，该股报15.40美元/股，成交量3.5016万股，换手率0.02%，振幅2.67%。Denali Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.60%。Denali Therapeutics Inc.公司简介：Denali Therapeutics Inc是一家生物技术公司，致力于开发和探索战胜神经变性疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223333abeb784b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223333abeb784b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","BK4139","DNLI","LENZ","BK4548"],"gpt_icon":0},{"id":"2517294201","title":"B. Riley Securities：重申Denali Therapeutics(DNLI.US)评级，由买入调整至买入评级, 目标价由38.00美元调整至35.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517294201","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517294201?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:22","pubTimestamp":1741195338,"startTime":"0","endTime":"0","summary":"B. Riley Securities：重申Denali Therapeutics(DNLI.US)评级，由买入调整至买入评级, 目标价由38.00美元调整至35.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06012248550715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","DNLI"],"gpt_icon":0},{"id":"2516510756","title":"奥本海默：维持Denali Therapeutics(DNLI.US)评级，由优于大市调整至优于大市评级, 目标价由50.00美元调整至42.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516510756","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516510756?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:00","pubTimestamp":1741024838,"startTime":"0","endTime":"0","summary":"奥本海默：维持Denali Therapeutics(DNLI.US)评级，由优于大市调整至优于大市评级, 目标价由50.00美元调整至42.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04020048498822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","DNLI"],"gpt_icon":0},{"id":"2516567096","title":"Denali Therapeutics Inc.盘中异动 快速下跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516567096","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516567096?lang=zh_cn&edition=full","pubTime":"2025-03-04 01:00","pubTimestamp":1741021227,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日01时00分，Denali Therapeutics Inc.股票出现异动，股价大幅跳水5.07%。Denali Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.05%。其相关个股中，Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为4043.54%、175.65%、144.19%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Denali Therapeutics Inc.公司简介：Denali Therapeutics Inc是一家生物技术公司，致力于开发和探索战胜神经变性疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304010027989a3215&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304010027989a3215&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4535","LENZ","DNLI","BK4548"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.denalitherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1201},{"period":"1month","weight":0.0772},{"period":"3month","weight":0.3225},{"period":"6month","weight":0.6108},{"period":"1year","weight":0.5914},{"period":"ytd","weight":0.361}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":-0.0375},{"period":"3month","weight":-0.0486},{"period":"6month","weight":-0.0076},{"period":"1year","weight":0.1414},{"period":"ytd","weight":-0.0368}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Denali Therapeutics Inc.于2013年10月在特拉华州注册成立。他们的目标是发现和开发可以战胜神经退行性疾病的治疗药物。神经退化代表了他们那个时代最重要的未得到满足的医疗需求之一，比如阿尔茨海默病，帕金森病疾病，肌萎缩性侧索硬化症或ALS，以及其他神经退化性疾病。这些疾病对患者和社会的负担是巨大的。他们相信现在正是他们利用强有力和雄心勃勃的努力来打败神经退化的正确时机。他们相信，他们可以在一个很少成功的领域取得了成就，因为他们拥有丰富的成功经验、热忱的科学家和药物开发者团队，他们专注的科学战略，以及他们专有的血脑屏障（BBB）平台输送技术。他们正在开发广泛的神经退行性疾病靶向治疗候选药物组合，并且最近开始了他们的第一个临床试验。他们于2015年5月开始运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.068767},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.02262},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.070649},{"month":4,"riseRate":0.625,"avgChangeRate":0.0118},{"month":5,"riseRate":0.75,"avgChangeRate":0.047446},{"month":6,"riseRate":0.625,"avgChangeRate":0.059984},{"month":7,"riseRate":0.375,"avgChangeRate":-0.046178},{"month":8,"riseRate":0.625,"avgChangeRate":0.067423},{"month":9,"riseRate":0.5,"avgChangeRate":0.021936},{"month":10,"riseRate":0.375,"avgChangeRate":-0.037447},{"month":11,"riseRate":0.625,"avgChangeRate":0.13715},{"month":12,"riseRate":0.375,"avgChangeRate":0.011033}],"exchange":"NASDAQ","name":"Denali Therapeutics Inc.","nameEN":"Denali Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Denali Therapeutics Inc.(DNLI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Denali Therapeutics Inc.(DNLI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Denali Therapeutics Inc.,DNLI,Denali Therapeutics Inc.股票,Denali Therapeutics Inc.股票老虎,Denali Therapeutics Inc.股票老虎国际,Denali Therapeutics Inc.行情,Denali Therapeutics Inc.股票行情,Denali Therapeutics Inc.股价,Denali Therapeutics Inc.股市,Denali Therapeutics Inc.股票价格,Denali Therapeutics Inc.股票交易,Denali Therapeutics Inc.股票购买,Denali Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Denali Therapeutics Inc.(DNLI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Denali Therapeutics Inc.(DNLI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}